Aligos Therapeutics Inc. and Katholieke Universiteit Leuven have jointly patented 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19), middle East respiratory syndrome coronavirus (MERS-CoV) infection, norovirus and rhinovirus infections.
Researchers from Aligos Therapeutics Inc. presented preclinical data for ALG-001075, a novel capsid assembly modulator leading to the formation of empty capsids (CAM-E), being developed for the treatment of hepatitis B.
Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.
Researchers from Aligos Therapeutics Inc. have presented the discovery and preclinical evaluation of a novel next-generation liver targeted PD-L1 small molecule inhibitor, ALG-094103, which is being developed for the treatment of chronic hepatitis B and liver cancer.
Aligos Therapeutics Inc. has disclosed programmed cell death protein 1 (PD-1; PDCD1; CD279), PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B virus (HBV).
Hepatocellular carcinoma (HCC) is the most frequent tumor of the liver, and in contrast to the reduction in the number of deaths in many common cancers, HCC’s mortality rates have gone up in recent years. One of the features that characterizes HCC is the activation of the Wnt/β-catenin signaling. Recent preclinical testing in HCC models has shown a reduction in tumor growth using siRNA or ASOs acting as β-catenin inhibitors.
Researchers from Aligos Therapeutics Inc. and the Katholieke Universiteit Leuven reported on the preclinical activity of ALG-097558, a novel oral available 3CL protease inhibitor with pan-coronavirus antiviral activity.
Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers.
Oric Pharmaceuticals Inc. is quitting development of ORIC-101 after interim analyses of two phase Ib studies concluded that the clinical activity does not justify going forward with the compound. The company was testing ORIC-101, a glucocorticoid receptor antagonist, combined with Abraxane in various solid tumors and paired with Xtandi in metastatic prostate cancer.
